Clinical Trial Results, Conference Calls, and Acquisitions - Research Report on Pfizer, UnitedHealth, Actavis, Bristol-Myers

 Clinical Trial Results, Conference Calls, and Acquisitions - Research Report
on Pfizer, UnitedHealth, Actavis, Bristol-Myers Squibb, and Quest Diagnostics

PR Newswire

NEW YORK, October 14, 2013

NEW YORK, October 14, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer
Inc. (NYSE: PFE), UnitedHealth Group Inc. (NYSE: UNH), Actavis Inc. (NYSE:
ACT), Bristol-Myers Squibb Co. (NYSE: BMY), and Quest Diagnostics Inc. (NYSE:
DGX). Today's readers may access these reports free of charge - including full
price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On October 9, 2013, Pfizer Inc. (Pfizer) announced top-line results from two
Phase 3 clinical trials of tofacitinib. Pfizer reported that tofacitinib is a
novel, oral, Janus kinase (JAK) inhibitor that is being investigated for the
treatment of adults with moderate-to-severe chronic plaque psoriasis: OPT
(Oral Psoriasis Treatment) Compare (A3921080) and OPT Retreatment (A3921111).
Pfizer revealed that top-line results from the OPT Compare study showed that
tofacitinib met the primary endpoint of non-inferiority to high-dose ENBREL at
the 10mg BID dose. Pfizer added that the OPT Retreatment study also met its
primary efficacy endpoints at the 5 and 10 mg BID doses by demonstrating that
a greater proportion of patients continuing tofacitinib treatment maintained
their response during the treatment withdrawal phase compared to patients who
switched to placebo. Pfizer informed that these are the first two of five
studies in the Phase 3 OPT Program. Pfizer further added that it expects
top-line results for the OPT Pivotal 1 and OPT Pivotal Phase 2 trials
(A3921078 and A3921079) in Q2 2014. The Full Research Report on Pfizer Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/d702_PFE]

UnitedHealth Group Inc. Research Report

On October 7, 2013, UnitedHealthcare, one of the businesses of UnitedHealth
Group Inc. (UnitedHealth), announced its 2014 portfolio of Medicare plans,
which features new ways for beneficiaries to save money on their Medicare
coverage. The Company reported that with the addition of Walmart to its
preferred retail pharmacy network and Pharmacy Saver program, customers who
enroll in UnitedHealthcare's stand-alone Part D plans and Medicare Advantage
plans that include drug coverage can save money on their medications at nearly
20,000 retail locations nationwide. UnitedHealthcare added that beneficiaries
can find additional benefits and services not available through Original
Medicare in UnitedHealthcare's Medicare Advantage plans, which will be
available in 44 states, the District of Columbia and most metropolitan areas
in 2014. Medicare beneficiaries may opt to make changes to their health
coverage during the Open Enrollment Period, beginning October 15, 2013. The
Full Research Report on UnitedHealth Group Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/73e5_UNH]

Actavis Inc. Research Report

On October 8, 2013, Actavis Inc. (Actavis) confirmed that it has filed an
Abbreviated New Drug Application (ANDA) with the US Food and Drug
Administration (FDA) seeking approval to market Buprenorphine Hydrochloride
and Naloxone Hydrochloride Sublingual Film 2mg/0.5 mg and 8mg/2 mg. The
Company reported that its ANDA product is a generic version of Reckitt
Benckiser Pharmaceuticals Inc.'s (Reckitt Benckiser) Suboxone Sublingual Film,
which is indicated for maintenance treatment of opioid dependence. In
connection with this, Reckitt Benckiser, RB Pharmaceuticals Ltd. and MonoSol
Rx LLC filed a suit against Actavis on October 8, 2013 in the U.S. District
Court for the District of Delaware seeking to prevent the Company from
commercializing its ANDA product prior to the expiration of certain US
patents. The Full Research Report on Actavis Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/4997_ACT]

Bristol-Myers Squibb Co. Research Report

On October 7, 2013, Bristol-Myers Squibb Co. (Bristol-Myers Squibb) reported a
correction to its release dated October 1, 2013, which announced the schedule
of its Q3 2013 results. According to the corrected release, the Company will
release its Q3 2013 results on Wednesday, October 23, 2013. The Company
further declared that Company executives will review financial information and
address inquiries from investors and analysts during a conference call to be
held at 10:00 a.m. ET on October 23, 2013. The Full Research Report on
Bristol-Myers Squibb Co. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/81a9_BMY]

Quest Diagnostics Inc. Research Report

On October 7, 2013, Quest Diagnostics Inc. (Quest Diagnostics) announced that
it acquired ConVerge Diagnostic Services, LLC (ConVerge) from Water Street
Healthcare Partners. Quest Diagnostics reported that this transaction includes
ConVerge's laboratory in Peabody, Massachusetts, and its patient service
centers operating in Massachusetts, New Hampshire and Connecticut. Steve
Rusckowski, President and CEO, Quest Diagnostics, said, "As a regional leader
in women's health that is also recognized for customer service, medical
expertise and innovation, ConVerge is a strong strategic fit with our
business. The addition of ConVerge to the Quest family will extend the range
of diagnostic information services patients and providers can access in the
region while also combining the considerable medical leadership of both
companies to spur new innovations that improve patient outcomes." Quest
Diagnostics informed that it expects the ConVerge transaction to be neutral to
adjusted EPS in 2013 and modestly accretive to EPS in 2014. Quest Diagnostics,
however, did not disclose the financial terms of the transaction. The Full
Research Report on Quest Diagnostics Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.analystscorner.com/r/full_research_report/05ba_DGX]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)